Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Maximum Tolerated Dose × Gynecologic × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Breast 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 122 Carboplatin 104 pembrolizumab 102 Bevacizumab 79 Cisplatin 59 Specimen Handling 56 olaparib 48 Magnetic Resonance Spectroscopy 43 Nivolumab 37 Biopsy 37 Gemcitabine 34 Taxes 31 niraparib 29 Cyclophosphamide 27 Blood Specimen Collection 26 Letrozole 23 dostarlimab 22 liposomal doxorubicin 21 lenvatinib 21 Drug Therapy 21 Doxorubicin 21 atezolizumab 19 Radiotherapy 19 Immunoglobulin G 19 fludarabine 18 Topotecan 18 Docetaxel 18 Disulfides 17 Brachytherapy 17 durvalumab 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡